Trial
NCT03846583
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Eli Lilly and Company
Condition
Breast Cancer
Intervention
Tucatinib
Why stopped
Study halted prematurely, prior to enrollment of first participant.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-23